RxRevu Revenue and Competitors

Location

N/A

Total Funding

Estimated Revenue & Valuation

  • RxRevu's estimated annual revenue is currently $15M per year.(i)
  • RxRevu's estimated revenue per employee is $192,308

Employee Data

  • RxRevu has 78 Employees.(i)
  • RxRevu grew their employee count by 4% last year.

RxRevu's People

NameTitleEmail/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$13M17718%N/AN/A
#2
$7.5M1299%N/AN/A
#3
$1.7M196%N/AN/A
#4
$190.9M15655%N/AN/A
#5
N/A6729%N/AN/A
#6
N/A5343%N/AN/A
#7
$7.5M190-2%N/AN/A
#8
$75M4399%N/AN/A
#9
N/A6632%N/AN/A
#10
N/A2-33%N/AN/A
Add Company

What Is RxRevu?

At RxRevu we believe in improving the value of healthcare through informed, consistent prescription decisions. We also believe that lasting changes require a dedicated intention and aligned effort, and we are committed to investing in the future of healthcare. We leverage our platform to deliver real-time, patient-specific cost information, electronic prior authorization, and therapeutic alternatives at the point of care. By doing so, we enable shared decisions between providers and patients, help patients get the right medication the first time, and remove friction from the point of care to fulfillment. We value mission-driven individuals with integrity, self-awareness, and curiosity. At RxRevu, we pride ourselves on a culture of fun, accountability, and autonomy, and working hard on interesting problems while maintaining a healthy work/life balance. Our goals: • Increasing medication adherence • Creating better outcomes for patients • Enhancing patient-prescriber conversations • Improving prescriber experiences • Solidifying real-time benefit check as a premier standard of care

keywords:N/A

N/A

Total Funding

78

Number of Employees

$15M

Revenue (est)

4%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$22.6M7813%N/A
#2
$19.5M788%N/A
#3
$7.5M7822%N/A
#4
$22.6M78-16%N/A
#5
$1.7M78-63%N/A